Loading
A phase 2 trial of Durvalumab, Oleclumab, Monalizumab in non-small-cell lung cancer, run by AstraZeneca, now recruiting.
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT05061550 by AstraZeneca, with 630 participants planned, started 2022-04-14 and due to reach its primary completion in 2030-05-28. Interventions recorded: Durvalumab, Oleclumab, Monalizumab, Dato-DXd, AZD0171. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Monalizumab, Oleclumab, CD73 / adenosine axis, AstraZeneca.
Shares Monalizumab, Oleclumab, CD73 / adenosine axis, Durvalumab.
Shares Oleclumab, CD73 / adenosine axis, Durvalumab, AstraZeneca.
Shares Oleclumab, CD73 / adenosine axis, AstraZeneca, Non-small-cell lung cancer.
Shares Datopotamab deruxtecan, Durvalumab, AstraZeneca, Cisplatin.
Shares Oleclumab, CD73 / adenosine axis, Datopotamab deruxtecan, Durvalumab.
Shares Datopotamab deruxtecan, Resectable stage I to III non-small-cell lung cancer, AstraZeneca, Cisplatin.
Shares Resectable stage I to III non-small-cell lung cancer, AstraZeneca, Cisplatin, Carboplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/